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ABSTRACT Two examples of large clinical trials for the treatment of 
advanced HIV disease are described. Chaloner and Rhame (1999) elicited 
prior opinions about the outcomes of the two trials from over 50 HIV clin-
icians. Their prior opinions are used here for design: the sample size for 
reaching consensus with high probability is calculated. Consensus is said to 
occur when all clinicians have posterior opinions which would lead to pre-
scribing the same treatment. Posterior beliefs are calculated using a simple 
linear Bayes approximation. In addition plots are given for determining pa-
rameter values for which a particular sample size is sufficient for consensus 
to be reached with high probability. These calculations are useful tools at 
the design stage and are simple to implement. 
1 Introduction 
The design of two large AIDS trials is examined. The trials were designed 
by the Community Program for Clinical Research in AIDS (CPCRA) a 
collaborative group, sponsored by the U.S. National Institutes of Health. 
Both trials examined long term treatment for the prevention of a common 
opportunistic infection, Pneumocystis carinii pneumonia (PCP) in patients 
with advanced HIV disease. For the two trials, Chaloner and Rhame elicited 
prior opinions from over 50 clinicians. These prior opinions are used here 
and details of the elicitation, with other uses of the opinions, are in Chaloner 
and Rhame (1999). 
Both these trials were large pragmatic trials aimed to influence clinical 
practice. The approach we take, therefore, is that when the trial is done, 
the data should be sufficient so that clinicians will generally have consen-
sus about what treatment to prescribe. Having the opinions elicited by 
Chaloner and Rhame for these two trials enables these calculations to be 
done for these two trials. 
2 Assumptions and Notation 
Suppose the two trials are both balanced designs with n independent Bernoulli 
observations on each treatment denoted { X n} and { }~ } . The probabilities 
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of PCP in two years are Bx and (Jy, respectively .• t and f· are the sample 
proportions for the two treatments. An normal approximation will be used 
to the posterior distribution of Bx and (Jy given the data, .. .-Y and Y. A 
different approximation, using the results of Hartigan (1969), was used in 
Tsai (1999). Hartigan's approximation requires prior means and variances 
for 0x and 8y but Chaloner and Rhame elicited prior means for Ox and 
Oy and only a prior variance for 8 x - 8y. The approximation used here is 
a normal approximation to the marginal posterior distribution for Bx -8y 
given the data X and Y. 
Specifically, denote the prior mean of 8x -9y as mx -my and the prior 
variance as r 2 • The distribution of X -Y, given (J x and 8y, is approximately 
normal with mean Bx - (}y and variance n-1u2 where u 2 = 8x(l - Ox)+ 
9y(l-0y ). So approximating both the prior distribution and the likelihood 
with that of a normal distribution gives a posterior mean, for 8 x - 8y, 
denoted µ(X, Y), of 
µ(S:, f·) 
nr2 - - u2 ~ 2 ., (X - Y) + 2 2 (mx - my). nr +u- nr +u 
Given Bx and Oy, therefore, 
Pr[µ("Y,Y) $ kl9x,9y] :::s Pr [x-Y $ k(n-r' +u•) ::.•(mx -my)l9x,9y] 
:::::; ~ ( K - ( (} x - Oy)) ' 
Jn-lu2 
where 
K = 
k(nr2 + u2 ) - u2 (mx - my) 
nr2 
This is an approximation to the sampling probability, given (} x and (Jy, 
that the posterior mean will be less than or equal to k. For the two trials 
Chaloner and Rhame elicited only the means for Ox and (Jy and a 95 % 
interval for Ox - (Jy. It is therefore assumed that if L is the length of the 
95% interval then L = 4r, or r 2 = £2 /16. 
2.1 Consensus 
Suppose opinions are documented from t clinicians. Consensus for prescrib-
ing X is defined, in the two examples, as all t clinicians having posterior 
means for Bx - Oy, µi(X, Y), i = I ... t, less than or equal to some value k. 
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Similarly they will agree in prescribing y· if µ;(.Y, f") > k, i = I. .. t. The 
value of k must be determined from the clinical context: k = 0 if treatments 
X and Y are similar in cost, toxicity and ease of adherence. 
For fixed Ox and Oy, where Ox - 0y ~ k, denote by nx the sample size 
needed to convince all clinicians to prescribe X. Similarly for Ox - Oy > 
k denote ny to be the sample size needed to convince all clinicians to 
prescribe Y. Specifically define nx to be the smallest sample size such that 
the probability, under the joint sampling distribution of X and Y, is at least 
1 - {J that µi ( X, Y) ~ k for all i = 1, ... , t. Similarly n y is the smallest 
sample size such that the probability, is at least 1 - {J that µi(X, Y) > k 
for all i = 1, ... , t. 
Under the sampling distribution of X, Y the events µi(X, Y) ~ k are 
dependent and nx will be the maximum of the individual sample sizes, ni, 
ni is the smallest n such that the probability that µi(X, Y) :5 k is at least 
1- {j. 
Note that the sampling distribution of X, Y for fixed Bx, 8y is used, not 
the predictive distribution of ...-Y, Y. Also the value u2 is specified from the 
values of 8x,8y. Both nx and ny therefore depend on Bx and Oy. 
3 The PCP Prophylaxis trials 
The CPCRA PCP-TMS trial compares two dosing regimens of trimetho-
prim sulfamethoxole (TMP-SMX) in HIV infected patients who are not 
known to be intolerant of the drug. TMP-SMX is believed to be the most 
effective drug that can prevent PCP, the most common infection in patients 
with advanced HIV disease. The standard dose is one double strength tablet 
daily (D) but a lower dose of a double strength tablet three times a week 
(T) was considered. The three times a week dosing could be associated 
with fewer side effects and toxicities and so may therefore be tolerable for 
longer and so more effective. Alternatively, it could be less effective as first, 
bioavailability will be less, and second, patients might find it harder to 
remember to take a dose just three times a week. 
A second trial was designed for patients who develop intolerance to TMP-
SMX. This PCP-INT2 trial compares two drugs, atovaquone and dapsone, 
in patients who are intolerant of TMP-SMX. Dapsone was the standard 
treatment for patients intolerant of TMP-SMX and atovaquone was a newly 
licensed drug, approved, and sometimes used, for treatment of PCP, but 
rarely used for preventive treatment. Insurance carriers typically would 
not cover atovaquone for the prevention of PCP and so clinicians would 
not prescribe it. 
For each trial, 58 clinicians were asked for their opinion about the pro-
portion of PCP after two years for each treatment, and a 95% interval for 
the difference of proportions (Chaloner and Rhame, 1998). There are more 
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details of the elicitation in their paper. 
Figure 1 is a plot of the elicited 95% intervals. Note that a complete joint 
probability distribution for the two probabilities was not specified. 
4 The PCP-T:rvIS Trial 
In this trial, daily (D) and three times a week (T) of TMP-SMX are com-
pared. Replacing X by D and Y by T in the previous notation let 8 D 
and OT be the probabilities of PCP in the two years after randomization. 
The discussion in the protocol argues that a difference of 8 D - Or between 
(-0.009, 0.009] is clinically unimportant and the two treatments would be 
deemed equivalent. As daily is easier for patients to remember, and the drug 
is extremely inexpensive daily dosing would be prescribed in this case. A 
clinician would therefore prescribe daily dosing if he or she had a posterior 
mean for B less than or equal to 0.009; otherwise, one double strength tablet 
three times a week would be prescribed. So the k of Section 2.1 is 0.009. 
The upper plot in Figure 1 shows the prior opinions on 8 for this trial. 
Among the 58 clinicians, 5 of them did not provide intervals and 53 prior 
beliefs are therefore used to calculate the sample size. There are only two 
clinicians who have a prior opinion that Tis clinically better than D: that 
is mo - mr > 0.009. 
4.1 Results for the PCP-TMS trial 
For the 53 prior distributions, no is calculated by convincing those clin-
icians who have mo - mr greater than 0.009. That is, under the joint 
sampling distribution of D and f', given Bo and OT, the optimal sample 
size no is the smallest n such that the probability that all the posterior 
means of OD - (JT ~ 0.009 is at least 1 - /3. 
no and nT are calculated numerically. Tables 1 and 2 give the sample 
sizes for /3 = 0.2 and a range of values of OD and BT. Note that the sample 
size is very big when 8o-8r is only a little smaller than 0.009. For example, 
a sample size of 89,031 for each treatment is needed to convince all 53 
clinicians when Oo is 0.212 and BT is 0.205. If OD= 0.092 and Br= 0.123, 
daily dosing would be considered to be meaningfully better and a sample 
size of 7 41 for each treatment will be sufficient to guarantee with probability 
at least 0.80 that all posterior means will be no greater than 0.009. 
The actual sample size in this trial was chosen to be 1250 in each group, 
using frequentist hypothesis testing calculations. For this sample size, Fig-
ure 2 gives the values of Bo and Br for which consensus will be reached on 
prescribing with probability at least 0.80. The shaded region is the region 
in which the actual sample size of 1250 is too small to reach consensus with 
probability at least 0.80. 
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5 The PCP-INT2 trial 
The PCP-INT2 trial was designed to compare two alternative drugs, dap-
sone (100mg PO daily) and atovaquone {1500mg PO daily). The index X 
is replaced by D ( dapsone) and Y is replaced by A ( atovaquone) in this 
example. In this trial, the protocol specifies that dapsone is said to be clin-
ically better than atovaquone if OD - BA is less than -0.06 and the range of 
equivalence is [-0.06,0.06]. Since dapsone is much less expensive than ato-
vaquone, dapsone would generally be prescribed if the effects of these two 
drugs were found equivalent. Therefore, the optimal sample size for pre-
scribing dapsone, denoted by n D, would be the smallest n such that with 
probability at least 1 - /3, all posterior means of (}D - OA will be less than 
or equal to 0.06. Similarly, nA is the smallest n such that all the posterior 
means of (JD - (JA are greater than 0.06 with probability at least 1 - {3. In 
this trial, 7 clinicians did not provide information about the results of this 
trial. Only 51 prior beliefs are used to calculate the sample size. 
5.1 Results for the PCP-INT2 trial 
In the PCP-INT2 trial, there was only one clinician who believed prior 
to the trial that atovaquone was clinically better; mD - mA was bigger 
than 0.06. The sample size is therefore smaller for reaching a consensus for 
prescribing dapsone than the sample size needed for reaching consensus for 
prescribing atovaquone. For /3 = 0.2, Tables 3 and 4 show numerical results 
for prescribing dapsone and atovaquone for some possible values of fJ D and 
(}A· 
For prescribing dapsone, the sample size nD is decreasing with 8 A as 8 D 
fixed and is increasing with 8 D when 8 A is fixed. H 8 D - 0 A is less than 
but close to 0.06, the needed sample size is much bigger. For 8D = 0.24 
and 0 A = 0.36, dapsone would be considered to be meaningfully better 
and a sample size of 60 for each treatment is sufficient to convince the 51 
clinicians. 
For prescribing atovaquone, nA is decreasing with OD for fixed OA and is 
increasing with (}A for fixed OD. If OD = 0.24 and BA = 0.12 then atovaquone 
is considered to be meaningfully better and the sample size needed would 
be 12,357 for each treatment. 
In this trial, the planned sample size was 700 (350 in each group). For 
this sample size, n = 350, Figure 3 shows values of OD and (}A for which 
consensus will be reached on prescribing with probability at least 0.80. In 
this plot the probability of consensus is less than 0.80 when OD and f)A are 
in the large shaded area. Note that with a sample size of 350 for each group, 
there is only a very small region (the dotted region) where (}A is close to 0 
and 8 D is close to 1 where consensus will be reached, with probability at 
least 0.80, to prescribe atovaquone. This is useful to know, and calls into 
question the usefulness of this trial. 
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6 Discussion 
The sample sizes needed for prescribing the "~on-standard" treatments are 
big for both trials. For prescribing the treatment atovaquone, in the PCP-
INT2 trial, the very big sample sizes are caused by a few prior opinions 
which could be argued to be unreasonable. For example, one clinician has 
a 95 % interval of [-0.01,0.01] and this length is too small to be reasonable 
given that little was known about the effectiveness of the two drugs at the 
time. Two clinicians have means for the difference of -0.13 and -0.1 with 
correspondent confidence interval [-0.13,-0.07] and [-0.1,-0.01]. These two 
prior opinions also do not look reasonable as, again, very little data was 
available on the two drugs at the time the beliefs were specified but these 
opinions correspond to very strong opinions. It therefore seems reasonable 
not to consider these prior beliefs. If these three outlying beliefs are omitted, 
the sample sizes become much smaller. 
7 Conclusions 
Spiegelhalter, Freedman and Parmar (1994) and others argue that a clin-
ical trial should stop when consensus would be reached in the scientific 
community about the primary result of a trial. The two trials considered 
here were trials with an objective of answering two questions: first what 
dose of TMP-SMX should be prescribed for PCP prophylaxis for patients 
who can tolerate TMP-SMX and second should dapsone or atovaquone be 
prescribed for patients who are intolerant of TMP-SMX. The methods de-
scribed here are simple tools which add to considerations of sample size. 
They indicate that for the first question, to be answered by the PCP-TMS 
trial, unless the two dosages are very similar in effect, the sample size of 
1250 on each treatment is probably large enough to reach consensus. For 
the second question if the answer is that dapsone should be used then con-
sensus will probably be reached, but the sample size is too small to reach 
consensus if the answer is atovaquone. This is an important consideration 
for design. 
Extensions to this work are in Tsai (1999). For example, an alternative 
approach is given there where just three prior distributions are specified, 
representing optimistic, pessimistic and skeptical opinions. The sample size 
is calculated for reaching consensus for these three prior opinions. For the 
two trials discussed here, however, given the wide diversity of opinion, using 
all the prior opinions elicited seems more appropriate. 
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Table 1: The Optimal Sample Sizes for Prescribing Daily Dosing in the 
PCP-TMS Trial for Possible Values of fJ D and Br 
8r 
0.041 0.082 0.123 0.164 0.205 0.305 0.405 0.505 
0.012 211 152 130 117 107 89 74 61 
0.032 737 260 185 153 133 104 84 68 
0.052 0 497 270 201 165 121 95 75 
0.072 0 1388 418 269 207 140 107 84 
(}D 0.092 0 0 741 374 263 163 120 92 
0.112 0 0 1896 556 342 190 135 102 
0.212 0 0 0 0 89031 494 249 165 
0.312 0 0 0 0 0 115090 594 284 
0.412 0 0 0 0 0 0 130359 641 
0.512 0 0 0 0 0 0 0 134837 
Table 2: The Optimal Sample Sizes for Prescribing One Double Strength 
Tablet Three Times a Week in the PCP-TMS Trial for Possible 
Values of (JD and Br 
8r 
0.041 0.082 0.123 0.164 0.205 0.305 0.405 0.505 
0.012 0 0 0 0 0 0 0 0 
0.032 0 0 0 0 0 0 0 0 
0.052 65810 0 0 0 0 0 0 0 
0.072 4503 0 0 0 0 0 0 0 
(JD 0.092 2580 306329 0 0 0 0 0 0 
0.112 1923 7804 0 0 0 0 0 0 
0.212 1045 1662 2910 6918 0 0 0 0 
0.312 782 1064 1464 2088 3229 0 0 0 
0.412 622 794 1007 1285 1666 3884 0 0 
0.512 498 616 752 915 1114 1899 4197 0 
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Table 3: The Optimal Sample Sizes for Prescribing Dapsone in the PCP-INT2 
Trial for Possible Values of 0v and 0,4 
fJA 
Do 0.04 0.09 0.14 0.19 0.24 0.29 0.34 0.39 0.44 0.49 0.54 
0.04 48 33 27 24 21 19 17 15 14 13 11 
0.09 1207 101 55 40 32 27 24 21 18 16 14 
0.14 0 2029 148 75 51 40 32 27 24 21 18 
0.19 0 0 2751 190 92 61 46 37 31 26 22 
0.24 0 0 0 3373 225 106 69 51 40 33 28 
0.29 0 0 0 0 3894 253 117 75 55 43 35 
0.34 0 0 0 0 0 4316 276 126 80 57 44 
0.39 0 0 0 0 0 0 4636 293 132 83 59 
0.44 0 0 0 0 0 0 0 4857 303 135 84 
0.49 0 0 0 0 0 0 0 0 4977 308 136 
0.54 0 0 0 0 0 0 0 0 0 4997 306 
0.59 0 0 0 0 0 0 0 0 0 0 4917 
Table 4: The Optimal Sample Sizes for Prescribing Atovaquone in the 
PCP-INT2 Trial for Possible Values of 8v and 0A 
fJA 
Do 0.04 0.09 0.14 0.19 0.24 0.29 0.34 0.39 0.44 
0.04 0 0 0 0 0 0 0 0 0 
0.09 0 0 0 0 0 0 0 0 0 
0.14 10383 0 0 0 0 0 0 0 0 
0.19 5431 15417 0 0 0 0 0 0 0 
0.24 3963 7464 19798 0 0 0 0 0 0 
0.29 3210 5166 9215 23524 0 0 0 0 0 
0.34 2722 4025 6189 10683 26597 0 0 0 0 
0.39 2361 3313 4708 7033 11869 29016 0 0 0 
0.44 2071 2806 3799 5260 7697 12773 30781 0 0 
0.49 1824 2413 3164 4183 5681 8181 13394 31893 0 
0.54 1606 2090 2682 3438 4462 5970 8486 13733 32351 
0.59 1408 1813 2292 2878 3626 4638 6127 8612 13789 
0.59 
10 
13 
16 
19 
23 
29 
36 
45 
59 
83 
134 
298 
0.49 0.54 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
32154 0 
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Figure 1: 95% prior belief intervals for both PCP-TMS trial and PCP-INT2 
trial. Dotted vertical line shows the value of k. 
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Figure 2: Values of (}D and 8r for which the probability of consensus on pre-
scribing is at least 0.80 when n is 1250 for each group in PCP-TMS trial. For 
n=1250, the probability of consensus is less than 0.80 if OD and Br lie in the 
shaded area. 
consensus will occur 
wilh probability at least 0.80 
!or prescribing daily dosing 
if n=1250 for each treabnent 
consensus will occur 
with probability at least 0.80 
for prescribing one double slrength tab lei 
three times a week 
ii n= 1250 for eadl treatment 
o...__..,___ _________________ ___, 
00.037 
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Figure 3: Values of Bo and 8A for· which the probability of consensus on pre-
scribing is at least 0.80 when n is 350 for each group in PCP-INT2 trial. For 
n=350, the probability of consensus on prescribing Atovaquone is at least 0.80 
if O o and Br lie in the dotted area. If Bo and 8 A lie in the shaded area, the 
actual sample size of 350 is too small to reach consensus with probability at 
least 0.80. 
consensus will occur 
with probabili~ at least 0.80 
for prescribing Dapsone 
if n:350 for each treatment 
o..._ _____________________ _ 
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